... Available SBML simulators do not fully support the integration, within open-standard simulation ecosystems, of SBML models with models defined using other languages. This severely hinders the possibility to co-simulate and integrate SBML models within large model networks comprising biochemical as well as other kinds of models, possibly at different levels of abstraction (multi-scale model networks, see, e.g., de Bono and Hunter, 2012), and applying standard systems engineering For example, the interconnection of quantitative models of the human physiology (e.g., Physiomodel, Mateják and Kofránek, 2015), drugs pharmacokinetics/pharmacodynamics (e.g., Open Systems Pharmacology Suite, Eissing et al., 2011), (possibly semi-autonomous) biomedical devices, pharmacological protocol guidelines or treatment schemes, enables the set-up of in silico clinical trials for the (model-based) safety and efficacy pre-clinical assessment of such drugs, protocols, treatments, devices, using standard system engineering approaches to perform their simulation-based analysis at system level (see, e.g., Kanade et al., 2009;Mancini et al., 2013Mancini et al., , 2014Zuliani et al., 2013;Zuliani, 2015;Mancini et al., 2016aMancini et al., , 2017. Works in this direction include, e.g., (Schaller et al., 2016;Messori et al., 2018), where a model-based verification activity of a sensor-augmented insulin pump is conducted against a model of the human glucose metabolism in patients with diabetes mellitus, (Madec et al., 2019), where a model of a penicillin bio-sensor (integrating biochemistry, electrochemistry, and electronics models) is simulated to compute a first dimensioning of the sensor, and (Tronci et al., 2014;Mancini et al., 2015), where representative populations of virtual patients are generated from parametric models of the human physiology, a key step to enable in silico clinical trials (see, e.g., Mancini et al., 2018). ...